devices.longevity.one
Atlas Photonic / Light Photobiomodulation / LLLT — Low-Level Light Therapy
Photonic / Light

Photobiomodulation / LLLT — Low-Level Light Therapy

Evidence-supportedBgradePlausibility · Plausible, groundedPhotonic / Light
Evidence-supported · Evidence-supported
Specific FDA-cleared uses (e.g., oral mucositis, certain pain / wound indications).
Off-label · Insufficient-evidence
Broad / systemic 'all-light-heals', cognitive, anti-aging claims.

Real photomedicine: red/NIR light on cytochrome-c-oxidase, with FDA-cleared specific uses; broad/systemic claims remain frontier. Distinct from methylene blue, which is redox pharmacology, not photobiomodulation.

Origin & lineage
Mainstream photomedicine.
Claimed mechanism
Red / NIR light (600–1000 nm) → cytochrome-c-oxidase → ATP↑, ROS↓.
Plausibility
Plausible, grounded — real photoacceptor; biphasic dose and wavelength / penetration matter.
Evidence — grade B
Mechanism solid; ~12 systematic reviews 2019–23 mostly positive; GRADE low; strongest in oral mucositis.
Market
Makers: Joovv; Vielight; Erchonia; THOR; LiteCure.
Models: Joovv panels; Vielight; Erchonia (510(k)s).
Price: Consumer panels $500–2K; clinical $2–20K+.

Kernel — keep vs set aside

Keep — real substrate
Real photoacceptor (cytochrome-c-oxidase); dose, wavelength and penetration are real, quantifiable levers.
Set aside — claim
'All frequencies heal' / broad systemic / anti-aging generalization is unsupported.

Regulatory status by jurisdiction

Registration or clearance is a market-access fact, never proof of efficacy.

US — FDAFDA-cleared specific uses; consumer panels unregulated for disease.
EU — MDRCE varies.
RussiaNot specified in source.
China — NMPANot specified in source.
Australia — TGANot specified in source.

Sources